Connect Biopharma Holdings Ltd.

General Information

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. The estimated global market for AD was approximately $10.4 billion in 2020 and is expected to grow to $19.3 billion by 2025, a compound annual growth rate, or CAGR, of 13.2%. 

(Note: Connect Biopharma upsized its IPO at pricing on March 18, 2021: 11.25 million shares, up from 9.4 million in the prospectus, were priced at $17 each – the high end of the deal’s $15-to-$17 range – to raise $191.25 million.)

Industry: Pharmaceuticals
Employees: 62
Founded: 2012
Contact Information
Address Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400
Phone Number +86 512 5357 7866.
Web Address
View Prospectus: Connect Biopharma Holdings Ltd.
Financial Information
Market Cap $863.1mil
Revenues $-30.3 mil (last 12 months)
Net Income $-119.4 mil (last 12 months)
IPO Profile
Symbol CNTB
Exchange NASDAQ
Shares (millions): 11.3
Price range $17.00 - $17.00
Est. $ Volume $191.3 mil
Manager / Joint Managers Jefferies/ SVB Leerink/ Piper Sandler/ CICC
CO-Managers -
Expected To Trade: 3/19/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change